News
Sydney skin cancer patients join the EPIC-Skin study as they undergo first treatments with OncoBeta's Rhenium-SCT
Garching, Munich. Germany – OncoBeta® GmbH has announced its first Sydney-based patients were treated with Rhenium-SCT® as part of the global phase IV…
EPIC-Skin study welcomes world-first skin cancer patients treated with OncoBeta’s Rhenium-SCT
Garching,Munich.Germany – OncoBeta® GmbH has today announced a world-first from Australia, with the first patients treated with Rhenium-SCT® as part…
EPIC-Skin study welcomes world-first skin cancer patients treated with OncoBeta’s Rhenium-SCT
Garching,Munich.Germany – OncoBeta® GmbH has today announced a world-first from Australia, with the first patients treated with Rhenium-SCT® as part…
EPIC-Skin study welcomes world-first skin cancer patients treated with OncoBeta’s Rhenium-SCT
Garching,Munich.Germany – OncoBeta® GmbH has today announced a world-first from Australia, with the first patients treated with Rhenium-SCT® as part…
First patients registered into OncoBeta’s International Registry for Non-Melanoma Skin Cancer treatments
The International Registry is an observational, multicentre, non-interventional program for patients diagnosed with non-melanoma skin cancer (NMSC),…
OncoBeta receives ethics approval for EPIC-Skin study to evaluate Rhenium-SCT in Australia
21st December 2021
Garching b. Munich, Germany – OncoBeta® GmbH, a medical device company specialized in innovative epidermal radioisotope therapies…
OncoBeta launches International Registry for Non-Melanoma Skin Cancer
23rd November 2021
Garching near Munich, Germany – OncoBeta® GmbH announces the launch of a first-of-its- kind International Registry for NMSC.…
South African non-melanoma skin cancer patients now have greater access in the area of Johannesburg to innovative non-invasive treatment Rhenium-SCT®
Lethabong, South Africa, 16 November 2021: Today OncoBeta® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies…
First non-melanoma skin cancer patients treated with the Rhenium-SCT® in Austria
Vienna, Austria, 28 October 2021: OncoBeta® GmbH, a medical device company specialized in innovative epidermal radioisotope therapies for non-melanoma…
OncoBeta initiates international EPIC-Skin study with Rhenium-SCT® for the treatment of Skin Cancer
The multi-centre prospective study will evaluate the efficacy of the Rhenium-SCT® in non-melanoma skin cancer patients
Garching n. Munich, Germany–…